Please assess the completion status of the following clinical trial:

Trial Title: High Dose Cyclophosphamide for Treatment of Scleroderma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meet established criteria for a diagnosis of diffuse cutaneous scleroderma and have evidence of moderately severe organ damage and clinical evidence of active disease.~* Patients with diffuse scleroderma who have evidence of active fibrosing alveolitis manifested by either a greater than 10% decline in the forced vital capacity or the diffusing capacity from the defined normal values or from baseline measurements.~* Patients with severe deforming localized scleroderma (generalized morphea, liner morphea, keloid or bullous scleroderma) that threatens their capacity to function normally in society.~Exclusion Criteria:~* Age less than 18 years and over 70 years~* Any risk of pregnancy~* Cardiac ejection fraction of \< 45%~* Serum creatinine \> 3.0~* Patients who are pre-terminal or moribund~* Bilirubin \> 2.0, transaminases \> 2x normal~* Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), (5/30/01) \< 50% predicted

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IV Cyclophosphamide (50 mg/kg) (Type: EXPERIMENTAL): This is an open-labeled single arm study of Cyclophosphamide (50 mg/kg) administered intravenously over 1 hour daily for four consecutive days (200 mg/kg total) through a Hickman catheter .

Based on this trial design, predict the completion outcome and termination type (if applicable).